Research Group: Vascular Malformations

Contact

Prof. Dr. Matthias Rath

Phone: +49 3834 / 86 53 96

e-mail: matthias.rath@med.uni-greifswald.de

Research interests

The focus of our research group lies on cerebral cavernous malformations (CCM) which are sometimes also called cavernous angiomas or cavernomas. These enlarged endothelial channels can be found in the venous-capillary bed of the central nervous system. They lack supporting pericytes and smooth muscle cells and tend to bleed. Haemorrhages into the neighbouring brain parenchyma may cause recurrent headaches, seizures and stroke-like symptoms.

Adapted from: Rath et al., J Med Genet. 2020;57(3):212-216.

CCMs may occur sporadically or in an autosomal dominant form. Familial CCM is caused by loss-of-function germline variants in one of three genes: CCM1/KRIT1, CCM2/OSM and CCM3/PDCD10. The prevalence of symptomatic carriers of a pathogenic CCM1, CCM2 or CCM3 variant is approximately 1:5,400-1:6,200. The first symptoms are usually reported in the second to fifth decade of life. However, one third of CCM patients are minors and 20% are younger than 10 years. Analyses of human CCM tissue samples with ultra-sensitive next generation sequencing technologies and immunohistochemistry have supported the hypothesis of a genetic two-hit mechanism in CCM formation (Figure). 

Adapted from: Schwefel et al., J Cell Mol Med. 2019;23(3):1771-1783.

The aim of our research group is to understand the pathogenesis of hereditary vascular malformations. For this purpose, we use next generation sequencing technologies and CRISPR/Cas9-mediated genome editing. Specifically, we have modelled the situation in human CCMs by highly efficient inactivation of CCM1, CCM2 or CCM3 in human endothelial cells using crRNA:tracrRNA:cas9 ribonucleoprotein transfection.

In new two- and three-dimensional cell culture models, we now try to clarify why endothelial cells have a survival advantage after inactivation of CCM1, CCM2 or CCM3 (Figure). By testing different pharmacological agents, we want to identify a new therapeutic approach. Pharmacotherapy is urgently needed for CCM patients for whom surgical resection is not an option.

 

Funding

Funding

  • Federal Ministry of Education and Research/BMBF (161L0276, 2021-2024)
  • DFG (RA2876/2-2, 2020-2022)
  • DFG (RA2876/2-1, 2017-2020)
  • DFG (FE432/9-1, 2014-2017)
  • EnVision (FP7-REGPOT-2010, 2011-2014)
  • BayGen (2006-2010).
  • DFG Research Training Group 1048 „Molecular basis of organ development in vertebrates“ (Zebrafish as model organism for cerebral cavernous malformations, 2008-2010)

Team Members

Team Members

Prof. Dr. Ute Felbor

Phone: +49 (0)3834 / 86 53 70
e-mail: ute.felbor@med.uni-greifswald.de

Prof. Dr. Matthias Rath

Phone: +49 3834 / 86 53 96
e-mail: Matthias.Rath@med.uni-greifswald.de

Dr. Dariush Skowronek

Phone: +49 3834 / 86 53 75
e-mail: Dariush.Skowronek@med.uni-greifswald.de

Dr. Robin Pilz

Phone: +49 3834 / 86 53 99
e-mail: RobinAlexander.Pilz@med.uni-greifswald.de

Dr. Christiane Much

Phone: +49 3834 / 86 53 68
e-mail: Christiane.Much@med.uni-greifswald.de

Valeriia Saenko, M. Sc. (PhD student)

Tel.: +49 (0)3834 / 86 53 99
E-Mail: Valeriia.Saenko@med.uni-greifswald.de

Lara Mellinger (MD student)

Tel.: +49 (0)3834 / 86 53 80

 

Barbara Sendtner (MD student)

Phone: +49 3834 / 86 53 80

Publications

Publications

  • Rath M, Pagenstecher A, Hoischen A, Felbor U. Postzygotic mosaicism in cerebral cavernous malformation. J Med Genet. 2020;57(3):212-216. doi:10.1136/jmedgenet-2019-106182
  • Schwefel K, Spiegler S, Kirchmaier BC, et al. Fibronectin rescues aberrant phenotype of endothelial cells lacking either CCM1, CCM2 or CCM3. FASEB J. 2020; 34: 9018– 9033. doi:10.1096/fj.201902888R
  • Schwefel K, Spiegler S, Much CD, Felbor U, Rath M. CRISPR/Cas9-mediated Generation of Human Endothelial Cell Knockout Models of CCM Disease. Methods Mol Biol. 2020;2152:169-177. doi:10.1007/978-1-0716-0640-7_13
  • Pilz RA, Schwefel K, Weise A, et al. First interchromosomal insertion in a patient with cerebral and spinal cavernous malformations. Sci Rep. 2020;10(1):6306. doi:10.1038/s41598-020-63337-5
  • Schwefel K, Spiegler S, Ameling S, et al. Biallelic CCM3 mutations cause a clonogenic survival advantage and endothelial cell stiffening. J Cell Mol Med. 2019;23(3):1771-1783. doi:10.1111/jcmm.14075
  • Moog U, Felbor U, Has C, Zirn B. Disorders Caused by Genetic Mosaicism. Dtsch Arztebl Int. 2020;116(8):119-125. doi:10.3238/arztebl.2020.0119
  • Skowronek D, Hebebrand M, Erber R, et al. Identification and characterization of a GLMN splice site variant in a family with glomuvenous malformations. Eur J Dermatol. 2020;30(2):179-181. doi:10.1684/ejd.2020.3716
  • Much CD, Schwefel K, Skowronek D, et al. Novel Pathogenic Variants in a Cassette Exon of CCM2 in Patients With Cerebral Cavernous Malformations. Front Neurol. 2019;10:1219. doi:10.3389/fneur.2019.01219
  • Spiegler S, Rath M, Much CD, Sendtner BS, Felbor U. Precise CCM1 gene correction and inactivation in patient-derived endothelial cells: Modeling Knudson's two-hit hypothesis in vitro. Mol Genet Genomic Med. 2019;7(7):e00755. doi:10.1002/mgg3.755
  • Pilz RA, Korenke GC, Steeb R, Strom TM, Felbor U, Rath M. Exome sequencing identifies a recurrent SOX2 deletion in a patient with gait ataxia and dystonia lacking major ocular malformations. J Neurol Sci. 2019;401:34-36. doi:10.1016/j.jns.2019.04.007
  • Rath M, Spiegler S, Strom TM, Trenkler J, Kroisel PM, Felbor U. Identification of pathogenic YY1AP1 splice variants in siblings with Grange syndrome by whole exome sequencing. Am J Med Genet A. 2019;179(2):295-299. doi:10.1002/ajmg.a.60700
  • Spiegler S, Rath M, Paperlein C, Felbor U. Cerebral Cavernous Malformations: An Update on Prevalence, Molecular Genetic Analyses, and Genetic Counselling. Mol Syndromol. 2018;9(2):60-69. doi:10.1159/000486292
  • Spiegler S, Rath M, Hoffjan S, et al. First large genomic inversion in familial cerebral cavernous malformation identified by whole genome sequencing. Neurogenetics. 2018;19(1):55-59. doi:10.1007/s10048-017-0531-7
  • Rath M, Korenke GC, Najm J, et al. Exome sequencing results in identification and treatment of brain dopamine-serotonin vesicular transport disease. J Neurol Sci. 2017;379:296-297. doi:10.1016/j.jns.2017.06.034
  • Rath M, Jenssen SE, Schwefel K, et al. High-throughput sequencing of the entire genomic regions of CCM1/KRIT1, CCM2 and CCM3/PDCD10 to search for pathogenic deep-intronic splice mutations in cerebral cavernous malformations. Eur J Med Genet. 2017;60(9):479-484. doi:10.1016/j.ejmg.2017.06.007
  • Rath M, Spiegler S, Nath N, et al. Constitutional de novo and postzygotic mutations in isolated cases of cerebral cavernous malformations. Mol Genet Genomic Med. 2016;5(1):21-27. Published 2016 Dec 20. doi:10.1002/mgg3.256
  • Spiegler S, Kirchmaier B, Rath M, et al. FAM222B Is Not a Likely Novel Candidate Gene for Cerebral Cavernous Malformations. Mol Syndromol. 2016;7(3):144-152. doi:10.1159/000446884
  • Spiegler S, Najm J, Liu J, et al. High mutation detection rates in cerebral cavernous malformation upon stringent inclusion criteria: one-third of probands are minors. Mol Genet Genomic Med. 2014;2(2):176-185. doi:10.1002/mgg3.60
  • Wüstehube J, Bartol A, Liebler SS, et al. Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc Natl Acad Sci U S A. 2010;107(28):12640-12645. doi:10.1073/pnas.1000132107
  • Pagenstecher A, Stahl S, Sure U, Felbor U. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet. 2009;18(5):911-918. doi:10.1093/hmg/ddn420
  • Voss K, Stahl S, Hogan BM, et al. Functional analyses of human and zebrafish 18-amino acid in-frame deletion pave the way for domain mapping of the cerebral cavernous malformation 3 protein. Hum Mutat. 2009;30(6):1003-1011. doi:10.1002/humu.20996
  • Stahl S, Gaetzner S, Voss K, et al. Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex. Hum Mutat. 2008;29(5):709-717. doi:10.1002/humu.20712

GfH-Posterpreis 2019 für Dr. Konrad Schwefel